Cargando…
Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive, large B-cell non-Hodgkin’s lymphoma. The prognosis of IVLBCL in patients with central nervous system recurrence after first-line chemotherapy treatment is extremely poor. Among immunotherapies, chimeric antigen receptor...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096123/ https://www.ncbi.nlm.nih.gov/pubmed/35574341 http://dx.doi.org/10.3389/fonc.2022.817969 |
_version_ | 1784705906113511424 |
---|---|
author | Liu, Wanying Li, Chunrui Cao, Yang Wang, Na Huang, Liang Shang, Zhen Wang, Jue Huang, Lifang Xu, Jinhuan Xiao, Min Zhang, Yicheng Zhou, Jianfeng Chen, Liting Xiao, Yi |
author_facet | Liu, Wanying Li, Chunrui Cao, Yang Wang, Na Huang, Liang Shang, Zhen Wang, Jue Huang, Lifang Xu, Jinhuan Xiao, Min Zhang, Yicheng Zhou, Jianfeng Chen, Liting Xiao, Yi |
author_sort | Liu, Wanying |
collection | PubMed |
description | BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive, large B-cell non-Hodgkin’s lymphoma. The prognosis of IVLBCL in patients with central nervous system recurrence after first-line chemotherapy treatment is extremely poor. Among immunotherapies, chimeric antigen receptor (CAR) T-cell immunotherapy has been recently found to be a highly effective treatment for B-cell lymphoma, especially for relapsed or refractory diffuse large B-cell lymphoma. However, no guidelines are available that provide a clear consensus regarding the management of patients with relapsed/refractory IVLBCL. Here, we report, for the first time, the use of autologous hematopoietic stem cell transplantation (ASCT) and CAR T-cell therapy in a patient with relapsed/refractory IVLBCL. CASE PRESENTATION: A 42‐year‐old woman was diagnosed with IVLBCL based on liver biopsy and developed central nervous system (CNS) progression. The patient received ASCT combined with murine monoclonal anti-CD19 and anti-CD22 CAR T-cell therapy. She achieved complete remission for 22 months so far with negative minimal residual disease and continues to be followed up. CONCLUSION: ASCT combined with CAR T-cell therapy was the best choice for treatment of relapsed/refractory IVLBCL, as it allowed the achievement of a lasting complete remission. |
format | Online Article Text |
id | pubmed-9096123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90961232022-05-13 Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report Liu, Wanying Li, Chunrui Cao, Yang Wang, Na Huang, Liang Shang, Zhen Wang, Jue Huang, Lifang Xu, Jinhuan Xiao, Min Zhang, Yicheng Zhou, Jianfeng Chen, Liting Xiao, Yi Front Oncol Oncology BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive, large B-cell non-Hodgkin’s lymphoma. The prognosis of IVLBCL in patients with central nervous system recurrence after first-line chemotherapy treatment is extremely poor. Among immunotherapies, chimeric antigen receptor (CAR) T-cell immunotherapy has been recently found to be a highly effective treatment for B-cell lymphoma, especially for relapsed or refractory diffuse large B-cell lymphoma. However, no guidelines are available that provide a clear consensus regarding the management of patients with relapsed/refractory IVLBCL. Here, we report, for the first time, the use of autologous hematopoietic stem cell transplantation (ASCT) and CAR T-cell therapy in a patient with relapsed/refractory IVLBCL. CASE PRESENTATION: A 42‐year‐old woman was diagnosed with IVLBCL based on liver biopsy and developed central nervous system (CNS) progression. The patient received ASCT combined with murine monoclonal anti-CD19 and anti-CD22 CAR T-cell therapy. She achieved complete remission for 22 months so far with negative minimal residual disease and continues to be followed up. CONCLUSION: ASCT combined with CAR T-cell therapy was the best choice for treatment of relapsed/refractory IVLBCL, as it allowed the achievement of a lasting complete remission. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9096123/ /pubmed/35574341 http://dx.doi.org/10.3389/fonc.2022.817969 Text en Copyright © 2022 Liu, Li, Cao, Wang, Huang, Shang, Wang, Huang, Xu, Xiao, Zhang, Zhou, Chen and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Wanying Li, Chunrui Cao, Yang Wang, Na Huang, Liang Shang, Zhen Wang, Jue Huang, Lifang Xu, Jinhuan Xiao, Min Zhang, Yicheng Zhou, Jianfeng Chen, Liting Xiao, Yi Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report |
title | Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report |
title_full | Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report |
title_fullStr | Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report |
title_full_unstemmed | Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report |
title_short | Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report |
title_sort | sequential car t-cell therapy after autologous stem cell transplantation for the treatment of relapsed/refractory intravascular large b-cell lymphoma with central nervous system involvement: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096123/ https://www.ncbi.nlm.nih.gov/pubmed/35574341 http://dx.doi.org/10.3389/fonc.2022.817969 |
work_keys_str_mv | AT liuwanying sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT lichunrui sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT caoyang sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT wangna sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT huangliang sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT shangzhen sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT wangjue sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT huanglifang sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT xujinhuan sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT xiaomin sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT zhangyicheng sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT zhoujianfeng sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT chenliting sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport AT xiaoyi sequentialcartcelltherapyafterautologousstemcelltransplantationforthetreatmentofrelapsedrefractoryintravascularlargebcelllymphomawithcentralnervoussysteminvolvementacasereport |